Ethosuximide

CHEMBL696 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

141.2 g/mol

LogP

0.4

Phase

4

This anticonvulsant medication works by blocking a specific type of calcium channel in brain cells that is responsible for the abnormal electrical activity causing absence seizures. It is the drug of choice for absence epilepsy.

Peso molecular

141,1700 g/mol

LogP

0,40

TPSA

46,20 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Cáncer colorrectal Cáncer de mama Cáncer de ovario Cáncer de páncreas Cáncer de próstata Cáncer de pulmón de células no pequeñas Cáncer de tiroides Cáncer de vejiga Epilepsia Migraña

Mecanismo de acción

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC1(C)CC(=O)NC1=O

InChI

InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)

Molecular Formula

C7H11NO2

HBD / HBA

1 / 2

Enlaces Rotables

1

Átomos Pesados

10

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

This anticonvulsant medication works by blocking a specific type of calcium channel in brain cells that is responsible for the abnormal electrical activity causing absence seizures. It is the drug of choice for absence epilepsy.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Ethosuximide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL696. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3291. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

¿Busca información accesible para el paciente?

Ethosuximide en PillFYI

Estructura

Datos Rápidos

Fórmula: C7H11NO2
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.